Cram The PANCE Anti-Obesity Pharmacology
Obesity Guidelines- Underweight: under anxiety
18.5 increase BP and HR
healthy: 18.5-24.9 CI:
overweight: 25-29.9 CV disease
hyperthyroidism
obesity: 30+ glaucoma
class 1: 30-34.9 drug abuse
class 2: 35-39.9 agitated states
class 3 (severe): 40+ *use during/within 2 weeks of MAO inhibitor
etc.:
AOM (General)- pregnancy controlled subtance
contraindications monitor vitals
diabetes on insulin/insulin secretagogues short term use only
weight loss=BG drops
reduced caloric consumption vs. insulin orlistat- ex: xenical
consumption alli
HTN w. pharm txt. moa: binds/inactivates gastric+pancreatic lipases
eating disorders (bulimia nervosa) in GI tract→can’t digest triglycerides→calorie
use iwth other mx deficit (sympathominetic)
dose: with fat containing meals
weight loss less than 5% from after 12 weeks don’t eat with fat-free meals
mass dose=switch/stop se:
monitor: GI:
weight loss flatulence+discharge (24%)
vitals oily spotting/stools (27%)
lifestyle modifications fecal urgency (22%)
ex: steaorrhea (20%)
phentermine ci:
orlistat chronic malabsorption syndrome
phentermine/topiramate cholestasis
naltrexone/buproprion levothyroxine
cyclosporines
phentermine- ex: adipex-p etc.: need MVI with fat soluble-vitamins
lomira separated by 2 hours
MOA: releases norepinephrine+reduced appetite
and decreased food consumption phenterine ER- ex: qsymia
Dose: PO 1-2x daily moa: binds/inactivates gastric+pancreatic lipases
SE: in GI tract→can’t digest triglycerides→calorie
GI: deficit (sympathominetic)
nausea dose: daily dose→increase from starting dose
constipation after 2 weeks
General: side effects:
dry mouth GI:
headache nausea
insomnia constipation
irritability General:
1/3
Obesity Guidelines- Underweight: under anxiety
18.5 increase BP and HR
healthy: 18.5-24.9 CI:
overweight: 25-29.9 CV disease
hyperthyroidism
obesity: 30+ glaucoma
class 1: 30-34.9 drug abuse
class 2: 35-39.9 agitated states
class 3 (severe): 40+ *use during/within 2 weeks of MAO inhibitor
etc.:
AOM (General)- pregnancy controlled subtance
contraindications monitor vitals
diabetes on insulin/insulin secretagogues short term use only
weight loss=BG drops
reduced caloric consumption vs. insulin orlistat- ex: xenical
consumption alli
HTN w. pharm txt. moa: binds/inactivates gastric+pancreatic lipases
eating disorders (bulimia nervosa) in GI tract→can’t digest triglycerides→calorie
use iwth other mx deficit (sympathominetic)
dose: with fat containing meals
weight loss less than 5% from after 12 weeks don’t eat with fat-free meals
mass dose=switch/stop se:
monitor: GI:
weight loss flatulence+discharge (24%)
vitals oily spotting/stools (27%)
lifestyle modifications fecal urgency (22%)
ex: steaorrhea (20%)
phentermine ci:
orlistat chronic malabsorption syndrome
phentermine/topiramate cholestasis
naltrexone/buproprion levothyroxine
cyclosporines
phentermine- ex: adipex-p etc.: need MVI with fat soluble-vitamins
lomira separated by 2 hours
MOA: releases norepinephrine+reduced appetite
and decreased food consumption phenterine ER- ex: qsymia
Dose: PO 1-2x daily moa: binds/inactivates gastric+pancreatic lipases
SE: in GI tract→can’t digest triglycerides→calorie
GI: deficit (sympathominetic)
nausea dose: daily dose→increase from starting dose
constipation after 2 weeks
General: side effects:
dry mouth GI:
headache nausea
insomnia constipation
irritability General:
1/3
